Picture of HANS BIOMED logo

042520 HANS BIOMED Income Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Annual income statement for HANS BIOMED, fiscal year end - September 30th, KRW millions except per share, conversion factor applied.

2020
September 30th
2021
September 30th
2022
September 30th
2023
September 30th
2024
September 30th
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue80,09859,09874,45978,03281,137
Cost of Revenue
Gross Profit42,51529,22945,68345,12351,747
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses92,62475,44273,16682,55380,507
Operating Profit-12,526-16,3441,293-4,521630
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-16,700-21,6173,501-23,532-6,631
Provision for Income Taxes
Net Income After Taxes-18,171-22,1264,923-24,092-7,800
Minority Interest
Net Income Before Extraordinary Items
Net Income-17,840-18,2896,147-23,045-7,223
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income-17,840-18,2892,369-23,045-7,223
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-1,207-2,053180-2,127-554
Dividends per Share